These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 23593992)

  • 1. Amyloid β, glutamate, excitotoxicity in Alzheimer's disease: are we on the right track?
    Esposito Z; Belli L; Toniolo S; Sancesario G; Bianconi C; Martorana A
    CNS Neurosci Ther; 2013 Aug; 19(8):549-55. PubMed ID: 23593992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Glutamate-related excitotoxicity neuroprotection with memantine, an uncompetitive antagonist of NMDA-glutamate receptor, in Alzheimer's disease and vascular dementia].
    Tanović A; Alfaro V
    Rev Neurol; 2006 May 16-31; 42(10):607-16. PubMed ID: 16703529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Memantine: targeting glutamate excitotoxicity in Alzheimer's disease and other dementias.
    Molinuevo JL; Lladó A; Rami L
    Am J Alzheimers Dis Other Demen; 2005; 20(2):77-85. PubMed ID: 15844753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alzheimer's disease and the glutamate NMDA receptor.
    Doraiswamy PM
    Psychopharmacol Bull; 2003; 37(2):41-9. PubMed ID: 14566213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The molecular basis of memantine action in Alzheimer's disease and other neurologic disorders: low-affinity, uncompetitive antagonism.
    Lipton SA
    Curr Alzheimer Res; 2005 Apr; 2(2):155-65. PubMed ID: 15974913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacology of acetylcholinesterase inhibitors and N-methyl-D-aspartate receptors for combination therapy in the treatment of Alzheimer's disease.
    Geerts H; Grossberg GT
    J Clin Pharmacol; 2006 Jul; 46(7 Suppl 1):8S-16S. PubMed ID: 16809810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rationale for combination therapy with galantamine and memantine in Alzheimer's disease.
    Grossberg GT; Edwards KR; Zhao Q
    J Clin Pharmacol; 2006 Jul; 46(7 Suppl 1):17S-26S. PubMed ID: 16809811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NMDA receptor antagonists. A new therapeutic approach for Alzheimer's disease.
    Farlow MR
    Geriatrics; 2004 Jun; 59(6):22-7. PubMed ID: 15224791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disease-modifying drugs in Alzheimer's disease.
    Ghezzi L; Scarpini E; Galimberti D
    Drug Des Devel Ther; 2013 Dec; 7():1471-8. PubMed ID: 24353405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuropathologic changes in Alzheimer's disease: potential targets for treatment.
    Wenk GL
    J Clin Psychiatry; 2006; 67 Suppl 3():3-7; quiz 23. PubMed ID: 16649845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contemporary issues in the treatment of Alzheimer's disease: tangible benefits of current therapies.
    Tariot PN
    J Clin Psychiatry; 2006; 67 Suppl 3():15-22; quiz 23. PubMed ID: 16649847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuroprotection by memantine against neurodegeneration induced by beta-amyloid(1-40).
    Miguel-Hidalgo JJ; Alvarez XA; Cacabelos R; Quack G
    Brain Res; 2002 Dec; 958(1):210-21. PubMed ID: 12468047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paradigm shift in NMDA receptor antagonist drug development: molecular mechanism of uncompetitive inhibition by memantine in the treatment of Alzheimer's disease and other neurologic disorders.
    Lipton SA
    J Alzheimers Dis; 2004 Dec; 6(6 Suppl):S61-74. PubMed ID: 15665416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glutamatergic dysfunctioning in Alzheimer's disease and related therapeutic targets.
    Zádori D; Veres G; Szalárdy L; Klivényi P; Toldi J; Vécsei L
    J Alzheimers Dis; 2014; 42 Suppl 3():S177-87. PubMed ID: 24670398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An update on drug treatment options of Alzheimer's disease.
    Allgaier M; Allgaier C
    Front Biosci (Landmark Ed); 2014 Jun; 19(8):1345-54. PubMed ID: 24896354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hippocampal Degeneration and Behavioral Impairment During Alzheimer-Like Pathogenesis Involves Glutamate Excitotoxicity.
    Olajide OJ; Gbadamosi IT; Yawson EO; Arogundade T; Lewu FS; Ogunrinola KY; Adigun OO; Bamisi O; Lambe E; Arietarhire LO; Oluyomi OO; Idowu OK; Kareem R; Asogwa NT; Adeniyi PA
    J Mol Neurosci; 2021 Jun; 71(6):1205-1220. PubMed ID: 33420680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent Progress in the Pharmacotherapy of Alzheimer's Disease.
    Khoury R; Patel K; Gold J; Hinds S; Grossberg GT
    Drugs Aging; 2017 Nov; 34(11):811-820. PubMed ID: 29116600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alzheimer's disease, β-amyloid, glutamate, NMDA receptors and memantine--searching for the connections.
    Danysz W; Parsons CG
    Br J Pharmacol; 2012 Sep; 167(2):324-52. PubMed ID: 22646481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease.
    Rogawski MA; Wenk GL
    CNS Drug Rev; 2003; 9(3):275-308. PubMed ID: 14530799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Efficacy of memantine in the treatment of Alzheimer's disease].
    Molinuevo Guix JL; Lladó Plarrumaní A
    Neurologia; 2005 Dec; 20(10):686-91. PubMed ID: 16317590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.